The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer

Impacto

Downloads

Downloads per month over past year

Orea Soufi, Alba and Castillo Lluva, Sonia and Salvador Tormo, Nélida and Martín Cabrera, Paola and Recuero, Silvia and Gabicagogeascoa, Estíbaliz and Moreno Valladares, Manuel and Mendiburu Eliçabe, Marina and Blanco Gómez, Adrián and Ramos Pittol, José Miguel and García Taboada, Elena and Ocaña, Alberto and Cimas, Francisco J. and Matheu, Ander and Álvarez López, Isabel and Velasco, Guillermo and Lorente, Mar (2021) The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer. Cancers, 13 (21). pp. 1-19. ISSN 2072-6694

[thumbnail of Orea-Soufi-DBYBM-The-Pseudokinase-TRIB3.pdf]
Preview
PDF
Creative Commons Attribution.

3MB

Official URL: https://doi.org/10.3390/cancers13215307



Abstract

Background: Tribbles pseudokinase 3 (TRIB3) has been proposed to both promote and restrict cancer generation and progression. However, the precise mechanisms that determine this dual role of TRIB3 in cancer remain to be understood. In this study we aimed to investigate the role of TRIB3 in luminal breast cancer, the most frequent subtype of this malignancy. Methods: We genetically manipulated TRIB3 expression in a panel of luminal breast cancer cell lines and analyzed its impact on cell proliferation, and the phosphorylation, levels, or subcellular localization of TRIB3 and other protein regulators of key signaling pathways in luminal breast cancer. We also analyzed TRIB3 protein expression in samples from luminal breast cancer patients and performed bioinformatic analyses in public datasets. Results: TRIB3 enhanced the proliferation and AKT phosphorylation in luminal A (HER2-) but decreased them in luminal B (HER2+) breast cancer cell lines. TRIB3 negatively regulated the stability of HER2 in luminal B breast cancer cell lines. TRIB3 expression was associated with increased disease-free survival and a better response to therapy in luminal breast cancer patients. Conclusions: Our findings support the exploration of TRIB3 as a potential biomarker and therapeutic target in luminal breast cancer.


Item Type:Article
Uncontrolled Keywords:TRIB3; Luminal breast cancer; HER2; AKT; tissue microarrays; cell signaling
Subjects:Medical sciences > Medicine > Oncology
Medical sciences > Biology > Biochemistry
ID Code:72721
Deposited On:07 Jun 2022 15:16
Last Modified:18 Jul 2022 10:09

Origin of downloads

Repository Staff Only: item control page